Effects of Tranexamic Acid on surgical tretament for severe nasal bleeding

Effects of intravenous Tranexamic Acid on surgical arterial ligations for severe epistaxis

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

REBEC

Registry ID

RBR-5stwwm

Enrollment

Unknown

Registered

2015-04-17

Start date

2013-10-01

Completion date

Unknown

Last updated

2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe epistaxis submitted to surgical arterial ligation

Interventions

Experimental Group: To 20 patients undergoing surgery for severe nasal bleeding 1g of Tranexamic Acid (equivalent to 20mL) will be administered intravenously, at the moment of induction of general ane

Drug

D02.241.223.268.860

Eligibility

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: Patients with severe spontaneous epistaxis; indication of surgical treatment; both genders; 18-90 years-old.

Exclusion criteria

Exclusion criteria: Formal contraindications to the use of tranexamic acid; acute vaso-occlusive disease; active intravascular coagulation; hypersensitivity to the components of the formula; known coagulopathy; use of oral anticoagulants; altered coagulation tests; use of the drug on the 7 days before inclusion in the study; patient's refusal to participate in the study;

Design outcomes

Primary

Measure	Time frame
Recurrence of nasal bleeding until 30 days after intervention, verified through interview with participants 7 and 30 days after surgery, with potive answer for any type of nasal bleeding	—

Secondary

Measure	Time frame
Secondary outcomes are not expected	—

Countries

Brazil

Contacts

Public ContactJOAO PAULO MANGUSSI COSTA GOMES

Universidade federal de São Paulo - Escola Paulista de Medicina (UNIFESP-EPM)

joaopauloemt@gmail.com+55 (11) 98278-5776

Outcome results

None listed

Source: REBEC (via WHO ICTRP)